UBS raised the firm’s price target on BioMarin (BMRN) to $114 from $113 and keeps a Buy rating on the shares.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BMRN:
- 3 Best Stocks to Buy Now, 8/5/2025, According to Top Analysts
- BioMarin Pharmaceutical: Strong Financial Performance and Promising Pipeline Justify Buy Rating
- BioMarin Pharmaceutical: Strong Financial Performance and Promising Future Drive Buy Rating
- BioMarin Pharmaceutical Inc. Reports Strong Q2 2025 Results
- Positive Outlook for BioMarin Pharmaceutical Driven by Strong Financial Performance and Growth Opportunities